Editorial Comment: Valuable Lessons Learned From Current Screening Programs for Pancreatic Ductal Adenocarcinoma

Gia A DeAngelis

AJR Am J Roentgenol . 2024 Jun 26. doi: 10.2214/AJR.24.31567. Online ahead of print.

Surgery for potentially resectable pancreatic ductal adenocarcinoma (PDA) only allows a few years' benefit within the still dismal 12% 5-year survival time frame.